header logo image


Page 521«..1020..520521522523..530540..»

Research at MDI Biological Laboratory explores novel pathways of regeneration and tumorigenesis – Bangor Daily News

May 31st, 2020 3:48 pm

BAR HARBOR Research by scientists at the MDI Biological Laboratoryis opening up new approaches to promoting tissue regeneration in organs damaged by disease or injury.

In recent years, research in regenerative biology has focused on stem cell therapies that reprogram the bodys own cells to replace damaged tissue, which is a complicated process because it involves turning genes in the cells nucleus on and off.

A recent paper in the journal Genetics by MDI Biological Laboratory scientist Elisabeth Marnik, Ph.D., a postdoctoral fellow in the laboratory of Dustin Updike, Ph.D., offers insight into an alternate pathway to regeneration: by recreating the properties of germ cells.

Germ cells, which are the precursors to the sperm and egg, are considered immortal because they are the only cells in the body with the potential to create an entirely new organism. The stem cell-like ability of germ cells to turn into any type of cell is called totipotency.

By getting a handle on what makes germ cells totipotent, we can promote regeneration by unlocking the stem cell-like properties of other cell types, said Updike. Our research shows that such cells can be reprogrammed by manipulating their cytoplasmic composition and chemistry, which would seem to be safer and easier than changing the DNA within a cells nucleus.

Using the tiny, soil-dwelling nematode worm, C. elegans, as a model, the Updike lab studies organelles called germ granules that reside in the cytoplasm (the contents of the cell outside of the nucleus) of germ cells. These organelles, which are conserved from nematodes to humans, are one of the keys to the remarkable attributes of germ cells, including the ability to differentiate into other types of cells.

In their recent paper entitled Germline Maintenance Through the Multifaceted Activities of GLH/Vasa in Caenorhabditis elegans P Granules, Updike and his team describe the intriguing and elusive role of Vasa proteins within germ granules in determining whether a cell is destined to become a germ cell with totipotent capabilities or a specific type of cell, like those that comprise muscle, nerves or skin.

Because of the role of Vasa proteins in preserving totipotency, an increased understanding of how such proteins work could lead to unprecedented approaches to de-differentiating cell types to promote regeneration; or alternatively, to new methods to turn off totipotency when it is no longer desirable, as in the case of cancer.

The increase in chronic and degenerative diseases caused by the aging of the population is driving demand for new therapies, said MDI Biological Laboratory President Hermann Haller, M.D. Dustins research on germ granules offers another route to repairing damaged tissues and organs in cases where therapeutic options are limited or non-existent, as well as an increased understanding of cancer.

Because of the complexity of the cellular chemistry, research on Vasa and other proteins found in germ granules is often overlooked, but that is rapidly changing especially among pharmaceutical companies as more scientists realize the impact and potential of such research, not only for regenerative medicine but also for an understanding of tumorigenesis, or cancer development, Updike said.

Recent research has found that some cancers are accompanied by the mis-expression of germ granule proteins, which are normally found only in germ cells. The mis-expression of these germ-granule proteins seems to promote the immortal properties of germ cells, and consequently tumorigenesis, with some germ-granule proteins now serving as prognosis markers for different types of cancer, Updike said.

Updike is a former postdoctoral researcher in the laboratory of Susan Strome, Ph.D., at University of California, Santa Cruz. Strome, who was inducted into the National Academy of Sciences last year, first discovered P granules more than 30 years ago. She credits Updike, who has published several seminal papers on the subject, with great imagination, determination and excellent technical skill in the pursuit of his goal of elucidating the function and biochemistry of these tiny organelles.

The lead author of the new study from the Updike laboratory, Elisabeth A. Marnik, Ph.D., will be launching her own laboratory at Husson University in Bangor, Maine, this fall. Other contributors include J. Heath Fuqua, Catherine S. Sharp, Jesse D. Rochester, Emily L. Xu and Sarah E. Holbrook. Their research was conducted at the Kathryn W. Davis Center for Regenerative Biology and Medicine at the MDI Biological Laboratory.

Updikes research is supported by a grant (R01 GM-113933) from the National Institute of General Medical Sciences (NIGMS), an institute of the National Institutes of Health (NIH). The equipment and cores used for part of the study were supported by NIGMS-NIH Centers of Biomedical Research Excellence and IDeA Networks of Biomedical Research Excellence grants P20 GM-104318 and P20 GM-203423, respectively.

We aim to improve human health and healthspan by uncovering basic mechanisms of tissue repair, aging and regeneration, translating our discoveries for the benefit of society and developing the next generation of scientific leaders. For more information, please visitmdibl.org.

See the original post:
Research at MDI Biological Laboratory explores novel pathways of regeneration and tumorigenesis - Bangor Daily News

Read More...

Impact of Covid-19 Outbreak on Regenerative Medicine Market 2020 Trends, Growth Opportunities, Demand, Application, Top Companies and Industry…

May 31st, 2020 3:48 pm

A report, added to the extensive database of verified Market Research titled Regenerative Medicine Market 2020 by Manufacturer, Region, Type and Application, Forecast up to 2026, is intended to highlight first-hand documentation of all the best implementations in the industry. The report contains an in-depth analysis of current and future market trends, segmentation, industrial opportunities and the future market scenario, taking into account the forecast years 2020 to 2026. It contains extremely important details on the key players in the Regenerative Medicine market as well as growth-oriented practices, that they normally use. The report examines a number of growth drivers and limiting factors. The key forecast information by region, type and application with sales and revenue from 2020 to 2026 is included in this report.

Request Sample Copy of this Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=7157&utm_source=WCS&utm_medium=001

Top 10 Companies in the Regenerative Medicine Market Research Report:

Competitive landscape:

The report examines the major players, including the profiles of the major players in the market with a significant global and / or regional presence, combined with their information such as related companies, downstream buyers, upstream suppliers, market position, historical background and top competitors based on the Sales with sales contact information.

Regional Description:

The Regenerative Medicine market was analyzed and a proper survey of the market was carried out based on all regions of the world. The regions listed in the report include: North America (United States, Canada, and Mexico), Europe (Germany, France, United Kingdom, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina , Colombia etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa). All these regions have been studied in detail and the prevailing trends and different possibilities are also mentioned in the market report.

Sales and sales broken down by application:

Sales and sales divided by type:

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Regenerative Medicine market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=WCS&utm_medium=001

Table of Content

1 Introduction of Regenerative Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Regenerative Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Regenerative Medicine Market, By Deployment Model

5.1 Overview

6 Regenerative Medicine Market, By Solution

6.1 Overview

7 Regenerative Medicine Market, By Vertical

7.1 Overview

8 Regenerative Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Regenerative Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=WCS&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

More:
Impact of Covid-19 Outbreak on Regenerative Medicine Market 2020 Trends, Growth Opportunities, Demand, Application, Top Companies and Industry...

Read More...

Regenerative Medicine Market to Witness a Pronounce Growth During 2017 to 2025 – 3rd Watch News

May 31st, 2020 3:48 pm

Regenerative Medicine Market: Snapshot

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe areVericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc.A large number of players are anticipated to enter the global market throughout the forecast period.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Original post:
Regenerative Medicine Market to Witness a Pronounce Growth During 2017 to 2025 - 3rd Watch News

Read More...

Regenerative Medicine Market 2020 Size, Share, Regional Growth, Trends, Methods, Applications, Equipment vendors, Business Prospects and Forecast to…

May 31st, 2020 3:48 pm

Global Regenerative Medicine market offers a detailed overview of the regional as well as local market. With the objective to offer a complete market overview the Regenerative Medicine market report includes regional competitive landscape for the number of major market service providers. Moreover, the Regenerative Medicine market report also provides a comprehensive analysis of the major market players in the regional and global regions. The Regenerative Medicine market report provides an in-depth analysis of the market growth aspects, opportunities, status, size in terms of value and volume, and market segmentation along with the market revenue. In addition, the report also studies market outlook and status of the global and major regions on the basis of product, application, and key market players.

Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/52

Additionally, the research report on Regenerative Medicine market provides a broad analysis of the market which includes market overview, production, producers, dimensions, price, value, growth rate, income, deals, export, consumption, and sales revenue of the global Regenerative Medicine market. On the other hand, the Regenerative Medicine market report also studies the market status for the forecast period.

However, this will help to increase the marketing opportunities across the world as well as major market providers. The global Regenerative Medicine market report also offers in depth coverage from the huge range of aspects as well as scenario to opportunities and future trends. The global Regenerative Medicine market report also contains the manufacturers data which may comprise price, shipment, revenue, interview record, gross profit, and business distribution which help the customers to know about the global Regenerative Medicine market competitive landscape better.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market

The Regenerative Medicine market research report also covers the extensive SWOT analysis, venture return investigation, and speculation attainability investigation. The Regenerative Medicine market report further describes a complete market dynamic such as opportunities, market drivers, as well as challenges prevalent in the global market to better understand the Regenerative Medicine market more deeply. In addition to this, the Regenerative Medicine market report also offers qualitative as well as qualitative analysis of very segment along with its revenues and investment details in the market. The Regenerative Medicine market research report also describes the leading continents as well as their major countries with the profiles of major players operating across the global market.

In addition to this, the Regenerative Medicine market report also provides helpful insights for every established and innovative players across the globe. Furthermore the Regenerative Medicine market report offers accurate analysis for the shifting competitive dynamics. This research report comprises a complete analysis of future growth in terms of the evaluation of the mentioned forecast period. The Regenerative Medicine market report offers a comprehensive study of the technological growth outlook over time to know the market growth rates. The Regenerative Medicine market report also includes progressive analysis of the huge number of different factors that are boosting or operating as well as regulating the Regenerative Medicine market growth.

For Any Query on the Regenerative Medicine Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

View post:
Regenerative Medicine Market 2020 Size, Share, Regional Growth, Trends, Methods, Applications, Equipment vendors, Business Prospects and Forecast to...

Read More...

Meat the Future: Film Review – Variety

May 31st, 2020 3:48 pm

Meat the Future is a slightly goofy title for a film that takes its subject very, very seriously. The wordplay feels like a token flourish of whimsy in Liz Marshalls quietly educational documentary about the rise of alternative, environmentally friendly but still animal-based meat, as if to gently beckon carnivorous viewers who might be expecting a dour lecture. That isnt on the cards here, however. Meat the Future unfolds as a thorough and persuasive presentation for a cutting-edge product that it wants us to start thinking about in normalized terms; its got too much to explain and advocate to leave much time for moral repudiation. Clean meat, as cell-grown protein has been branded by the scientists developing it, is the future; Marshalls doc treats the present as a formality to be politely put behind us.

Selected to premiere as a special presentation at Hot Docs and currently streaming as part of the Toronto-based festivals online edition this smoothly assembled, information-led doc should transfer easily to television slots and VOD platforms, where itll connect with general audiences who may have encountered the subject of slaughter-free meat via buzzword-heavy magazine articles, but havent got into the chewier details. It gives us an amiable, reassuring guide in the form of Dr. Uma Valeti, an Indian-born cardiologist turned CEO of trailblazing clean meat startup Memphis Meats, who is quick to clarify what his passion product is not: Its not, he insists, lab-grown, cloned, in vitro, or any of the more daunting, clinical terms thrown around by advocates of more traditional butchery.

What it is is at once elegantly simple and kind of mind-blowing: at the edge of human knowledge, one Memphis Meats scientist claims, in a rare moment of hyperbolic extravagance. With equivalent tissue-engineering techniques to those used in regenerative medicine, scientists effectively cultivate flesh from the cells of living animals, resulting in a product allegedly closer in taste and texture to traditional meat than any plant-based alternative which is hardly surprising given the biological roots of it all, except that this technology results in no animal death or waste. Marshall doesnt glide through these nitty-gritties as if dispensing with the the science part in a shampoo commercial: Rather, the better part of the film is given over to Valeti and his colleagues repeated explanations and illustrations of how the sausage, so to speak, is made.

This may not be the stuff of exhilarating cinema, but neither is it dull. Meat the Future is a substance-over-style doc that manages the rare trick of being at once dry and rather engrossing: Over 90 minutes, its methodical, explicatory approach affords viewers of various dietary persuasions ample space to consider their own gastronomic preferences, preconceptions and prejudices. Marshall, who established her eco-doc credentials with 2013s crowdpleasing animal-rights study The Ghosts in Our Machine, isnt out to break a rhetorical sweat arguing us into a position: Like the smiling, soft-spoken Dr. Valeti, she provides enough facts and yes, in brief, horrifying footage from vast American factory farms, just enough of an emotional tug for us to argue ourselves there.

A handful of opposing views are introduced via footage from a combined FDA and USDA conference on the future branding of clean meat, prompted by protests from traditional livestock farmers that the miracle product shouldnt legally be permitted to use the m-word at all. Representatives from various American cattlemens associations many of them amusingly attired to type in Stetson hats and fringe jackets say their piece, but the film doesnt work up an argumentative head of steam. Between the cool, pale tones of its camerawork and graphics and the measured, conversational rhythm of its editing, Meat the Future aims for the same air of high-road calm as the burgeoning industry it depicts.

Still, one does wish for a slightly wider, more colorful range of perspectives here. Were treated to the impressed responses of various scientists and journalists as they chow down on cultivated meatballs, duck cutlets and clean but enticingly greasy fillet of fried chicken but the film misses a trick by not getting any restaurateurs or food personalities to weigh in on its merits. Where clean meat fits into a world increasingly drawn toward plant-based cuisine, meanwhile, is another intriguing avenue that goes unexplored: Surely the thoughts of an expert vegan advocate or two would further test and enrich the films compelling case for kinder carnivorousness.

See the article here:
Meat the Future: Film Review - Variety

Read More...

Coronavirus business impact: Carbon Fibre Application to Biomaterials Market 10-year Forecast and Trends Analysis Research Report – Jewish Life News

May 31st, 2020 3:48 pm

The report on the Carbon Fibre Application to Biomaterials market provides a birds eye view of the current proceeding within the Carbon Fibre Application to Biomaterials market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Carbon Fibre Application to Biomaterials market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Carbon Fibre Application to Biomaterials market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

As per the presented market report, the global Carbon Fibre Application to Biomaterials market is projected to attain a CAGR growth of ~XX% during the assessment period and surpass a value of ~US$XX by the end of 20XX. Further, the report suggests that the growth of the Carbon Fibre Application to Biomaterials market hinges its hope on a range of factors including, emphasis on innovation by market players, surge in the investments pertaining to R&D activities, and favorable regulatory policies among others.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2568519&source=atm

Competition Landscape

The report provides critical insights related to the business operations of prominent companies operating in the Carbon Fibre Application to Biomaterials market. The revenue generated, market presence of different companies, product range, and the financials of each company is included in the report.

Regional Landscape

The regional landscape section of the report provides resourceful insights related to the scenario of the Carbon Fibre Application to Biomaterials market in the key regions. Further, the market attractiveness of each region provides players a clear understanding of the overall growth potential of the Carbon Fibre Application to Biomaterials market in each region.

End-User Analysis

The report provides a detailed analysis of the various end-users of the Carbon Fibre Application to Biomaterials along with the market share, size, and revenue generated by each end-user.

The following manufacturers are covered:ACS MaterialeSpin TechnologiesGrupo AntolinLitmus NanotechnologyCarbon Nanomaterial TechnologyGraphenanoNanographite MatericalsPyrograpg ProsuctsAIXTRONPyrograf ProductsApplied SciencesEMFUTUR Technologies

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeCarbon NanofibersOther

Segment by ApplicationRegenerative MedicineCancer TreatmentOther

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2568519&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2568519&licType=S&source=atm

Visit link:
Coronavirus business impact: Carbon Fibre Application to Biomaterials Market 10-year Forecast and Trends Analysis Research Report - Jewish Life News

Read More...

Regenerative Medicine Market – Rising focus on cell therapy products drive the market growth – BioSpace

May 31st, 2020 3:47 pm

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=1889&ltype=S

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Read more here:
Regenerative Medicine Market - Rising focus on cell therapy products drive the market growth - BioSpace

Read More...

Impact of Covid-19 on Agricultural Biotechnology Market Outlook, Revenue, Trends and Forecasts Research Report 2020-2028 – Azizsalon News

May 31st, 2020 3:46 pm

Agricultural Biotechnology Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

Sample Copy of This Report:https://www.quincemarketinsights.com/request-sample-67083

A 360 degree outline of the competitive scenario of the Global Agricultural BiotechnologyMarket is presented by QuinceMarketInsights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Key players: KWS SAAT SE & Co. KGaA, ChemChina, Limagrain, Nufarm, Marrone Bio Innovations, Performance Plants Inc., Corteva, ADAMA Ltd, MITSUI & CO., LTD, Evogene Ltd., Valent BioSciences LLC, and Bayer AG.

Reasons for buying this report:

By Application (Vaccine, Flower Culturing, Biofuels)

By Organism (Plants, Animals, Microbes)

Get Discount on This Report: https://www.quincemarketinsights.com/request-discount-67083

A detailed outline of the Global Agricultural BiotechnologyMarket includes a comprehensive analysis of different verticals of businesses. North America, Europe, Asia Pacific, Middle East & Africa, and South America have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global Agricultural BiotechnologyMarket over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Agricultural BiotechnologyMarket are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Agricultural BiotechnologyMarket. The feasibility of the new report is also measured in this research report.

If You Have Any Query, Ask Our Experts:https://www.quincemarketinsights.com/enquiry-before-buying-67083

Table of Contents:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 121 364 6144

Email:sales@quincemarketinsights.com

Web:https://www.quincemarketinsights.com

Read the rest here:
Impact of Covid-19 on Agricultural Biotechnology Market Outlook, Revenue, Trends and Forecasts Research Report 2020-2028 - Azizsalon News

Read More...

UNITY Biotechnology to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference – GlobeNewswire

May 31st, 2020 3:46 pm

SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the upcoming Goldman Sachs 41st Annual Global Healthcare Conference.

Goldman Sachs 41st Annual Global Healthcare Conference

Date: June 11, 2020Fireside Chat Time: 3:50 PM E.T. Location: Virtual

A live audio webcast of the fireside chat will be available through the Investors & Media section of UNITYs website. An archived replay will be available for 90 days following the event.

About UNITYUNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at it source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Investors Endurance AdvisorsMike Zanonimzanoni@enduranceadvisors.com

Media Canale CommunicationsJason Sparkjason@canalecomm.com

Read this article:
UNITY Biotechnology to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference - GlobeNewswire

Read More...

Food Biotechnology Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 – Cole of Duty

May 31st, 2020 3:46 pm

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Food Biotechnology market.

Trusted Business Insights presents an updated and Latest Study on Food Biotechnology Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Food Biotechnology market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Food Biotechnology Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Food Biotechnology MarketIndustry / Sector Trends

Global Food Biotechnology Market size was valued at over USD 23 billion in 2018 and is anticipated to witness over 10% CAGR up to 2025.

Increasing penetration of advanced technologies to develop new products by modifying plants, animals, and microorganisms genes to provide innovative solutions is driving the market growth. Shifting trends towards healthy lifestyles accompanied by a rise in processed food demand has urged the F&B manufacturers to improve the nutritional content in their products, thereby generating new growth opportunities for the biotech-based industry players. Further, there is a requirement to enhance the shelf life and taste of food by the use of encapsulation techniques and other ingredients.

Strong growth in functional food & beverages and dietary supplements industry is resulting in increased competitiveness, thus propelling the food biotechnology market revenue. As per CCI, the global nutraceutical market including functional F&B and dietary supplements is projected to reach USD 241 billion in 2019, observing around 7% CAGR from 2014 to 2019. Factors such as robust expansion of food industry and low-cost biotech services particular in developing countries has escalated the adoption of services.

Stringent government regulations to enhance product quality and transparency are among the foremost aspects attributing to food biotech solutions. Also, modifications in labeling regulations asking for a declaration of GMOs, allergens, and nutritional content is surging the industry share. Further, consumer-driven movements such as clean label has urged food manufacturers to improve the quality by using natural ingredients instead of artificial constituents.

Changes in climatic conditions over the years has resulted in increased production of genetically modified (GM) crops or ingredients through the use of biotech services. This provides plants with improved resistance to diseases, insecticides, and herbicides, as well as extending the shelf life of the produce. However, growth in the organic food industry can hamper the demand for GM crops, thus affecting the food biotechnology industry share.

Market Segmentation, Outlook & Regional Insights: Food Biotechnology Market

Food Biotechnology Market, By Type

Transgenic segment dominates the global market accounting for over 75% share in 2018. Increasing demand for genetically modified crops to enhance productivity in low producing or harsh climatic conditions will drive segment growth. According to ISAAA, the global utilized area for biotech crops increased from 148 million hectares in 2010 to 190 million hectares in 2017. Countries including the U.S., Brazil, Argentina, Canada, and India holds over 90% of the total area under GM crop cultivation. Farmers shifting from conventional seeds to bio-seeds to improve their profit margins will escalate the market growth.

Germany Food Biotechnology Market Size, By Type, 2018 (USD Million)

Food Biotechnology Market, By Application

Global food biotechnology market through animal segment holds over 34% share in 2018. Increasing necessity to enhance milk production in dairy cattle with growing demand will propel industry expansion. Robust growth in meat consumption such as processed meat accompanied by increasing consumer awareness on nutritional benefits will drive the biotech applications. As per FAO, global meat production is projected to increase, reach around 48MT by 2025. Further, testing services for developing products to suit the human dietary requirements will drive market development.

Global food biotechnology market through plants is projected to account for over USD 22 billion in 2025. The key growth factors include an increase in the development of GM crops with pesticide resistance and abiotic stress tolerance to increase the yield. Reduction in the arable land area will further shift the preference towards biotechnological products. Enhanced focus on innovation of new food ingredients will surge the business revenues. Strong application outlook of biotech solutions to produce high-quality crops and reduce the health risk will augment business expansion.

Food Biotechnology Market, By Region

North America market is anticipated to cross USD 12 billion by 2025. High investments on technological advancements coupled with high consumer spending on nutritious products will augment the industry share. The U.S. is the largest producer of genetically modified crops with 75 million hectares area for biotech crops. Further, the presence of large multinational corporations, increasing private and government R&D investments, supported by favourable government policies will fuel the market growth. Further, positive application outlook of genetically modified yeast in developing new alcoholic beverages will support regional growth.

Asia Pacific Food Biotechnology Market, By Country, 2018 & 2025, (USD Million)

Asia Pacific food biotechnology market is projected to witness over 11% CAGR from 2019 to 2025. Countries including China, India, and Japan together dominate the regional market share. The demand for dietary supplements is increasing due to a shifting trend towards healthy lifestyles, thus increasing the demand for nutritional ingredients. Also, product innovations supported by the rise in per capita income will drive the biotech solutions on health foods. Further, the necessity to augment the agricultural output owing to the rise in population, along with severe climatic variations will drive the biotechnology industry share.

Key Players, Recent Developments & Sector Viewpoints: Food Biotechnology Market

Global market is competitive due to the presence of large multinationals and regional players. Key industry participants in market include BASF SE, Bayer CropScience AG, AquaBounty Technologies, ABS Global, Dow AgroSciences LLC, Arcadia Biosciences, Camson Bio Technologies Ltd, BDF Ingredients Zuchem, and Monsanto. Product development, geographic expansion, mergers, acquisitions, and collaborations are among the key strategies observed in the industry. For instance, in 2017, Bayer and Ginkgo Bioworks announced to launch a company to developing new technologies for engineering the plant microbiome.

Industry Viewpoint

Food biotechnology market is driven by the requirement for improving the productivity and quality of the edible items by altering genes. Growth in the food & beverages industry, increasing population, rising disposable incomes, and health awareness are among the major factors creating a long-term positive impact. Biotechnological product innovations among food manufacturers will provide lucrative opportunities for business growth. North America and Europe are among the early adopters of biotech services, however developing regions are also expected to implement advanced solutions in food industry. The penetration rate is high in Asia Pacific owing to strong R&D investments and the necessity for increasing the food productivity and animal milk output

Key Insights Covered: Exhaustive Food Biotechnology Market1. Market size (sales, revenue and growth rate) of Food Biotechnology industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Food Biotechnology industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Food Biotechnology industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Food Biotechnology industry.

Research Methodology: Food Biotechnology Market

Quick Read Table of Contents of this Report @ Food Biotechnology Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read the original post:
Food Biotechnology Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty

Read More...

Impact of Covid-19 Outbreak on Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Trends, Growth Opportunities, Demand, Application, Top…

May 31st, 2020 3:46 pm

A report, added to the extensive database of verified Market Research titled Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 by Manufacturer, Region, Type and Application, Forecast up to 2026, is intended to highlight first-hand documentation of all the best implementations in the industry. The report contains an in-depth analysis of current and future market trends, segmentation, industrial opportunities and the future market scenario, taking into account the forecast years 2020 to 2026. It contains extremely important details on the key players in the Nanoparticles in Biotechnology and Pharmaceuticals market as well as growth-oriented practices, that they normally use. The report examines a number of growth drivers and limiting factors. The key forecast information by region, type and application with sales and revenue from 2020 to 2026 is included in this report.

Request Sample Copy of this Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=WCS&utm_medium=001

Top 10 Companies in the Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report:

Competitive landscape:

The report examines the major players, including the profiles of the major players in the market with a significant global and / or regional presence, combined with their information such as related companies, downstream buyers, upstream suppliers, market position, historical background and top competitors based on the Sales with sales contact information.

Regional Description:

The Nanoparticles in Biotechnology and Pharmaceuticals market was analyzed and a proper survey of the market was carried out based on all regions of the world. The regions listed in the report include: North America (United States, Canada, and Mexico), Europe (Germany, France, United Kingdom, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina , Colombia etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa). All these regions have been studied in detail and the prevailing trends and different possibilities are also mentioned in the market report.

Sales and sales broken down by application:

Sales and sales divided by type:

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Nanoparticles in Biotechnology and Pharmaceuticals market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=WCS&utm_medium=001

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=WCS&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

More here:
Impact of Covid-19 Outbreak on Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Trends, Growth Opportunities, Demand, Application, Top...

Read More...

A Rapid Response Regulatory enabling mechanism facilitated by Department of Biotechnology for COVID 19 – India Education Diary

May 31st, 2020 3:46 pm

New Delhi: The Department of Biotechnology has taken several proactive measures to streamline the biosafety regulation and to facilitate researchers and industries which are undertaking research and development in Recombinant DNA Technology and Hazardous Microorganisms.

1. Operationalization of Indian Biosafety Knowledge Portal. The Indian Knowledge Biosafety Portal launched in May, 2019 was made fully operationalized and now the Department is receiving all new applications through online portal only. This has made the whole process transparent and time bound.

2. Notification of Revised Simplified Guidelines on Import, Export and Exchange of GE Organisms and Product Thereof for R&D Purpose: The Department issued the Revised Guidelines in January, 2020 in which Institutional Biosafety Committee have been delegated authority to take decisions on applications of import export and exchange of GE organisms and product thereof for R&D purpose for RG1 and RG2 items.

3. Facilitation of Research and Development on COVID-19: Considering the emerging situations of spread of Coronavirus and with the understanding on requirement of rapid research and development for COVI-19, the Department has proactively taken several steps to facilitate researchers and industries involved in research on COVID19. DBT has issued following guidelines, orders and checklist on COVID 19:

Rapid Response Regulatory Framework for COVID-19 to deal with application for development of vaccines, diagnostics, prophylactics and therapeutics has been notified on 20.03.2020DBT notified Interim Guidance Document on Laboratory Biosafety to Handle COVID-19 Specimens on 08.04.2020.IBSCs are allowed to conduct their meeting through video conferencing up to 30thJune, 2020.Rapid response regulatory framework for development of recombinant DNA COVID 19 vaccine was issued on 26.05.2020.

Read more:
A Rapid Response Regulatory enabling mechanism facilitated by Department of Biotechnology for COVID 19 - India Education Diary

Read More...

COVID-19: Responding to the business impacts of Pharmaceutical & Biotechnology Environmental Monitoring Market Trends and Segments 2019-2027 …

May 31st, 2020 3:46 pm

A recent market study on the global Pharmaceutical & Biotechnology Environmental Monitoring market reveals that the global Pharmaceutical & Biotechnology Environmental Monitoring market is expected to reach a value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% during the forecast period (2019-2029).

The Pharmaceutical & Biotechnology Environmental Monitoring market study includes a thorough analysis of the overall competitive landscape and the company profiles of leading market players involved in the global Pharmaceutical & Biotechnology Environmental Monitoring market. Further, the presented study offers accurate insights pertaining to the different segments of the global Pharmaceutical & Biotechnology Environmental Monitoring market such as the market share, value, revenue, and how each segment is expected to fair post the COVID-19 pandemic.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2641259&source=atm

The following doubts are addressed in the market report:

Key Highlights of the Pharmaceutical & Biotechnology Environmental Monitoring Market Report

The presented report segregates the Pharmaceutical & Biotechnology Environmental Monitoring market into different segments to ensure the readers gain a complete understanding of the different aspects of the Pharmaceutical & Biotechnology Environmental Monitoring market.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2641259&source=atm

Segmentation of the Pharmaceutical & Biotechnology Environmental Monitoring market

Competitive Outlook

This section of the report throws light on the recent mergers, collaborations, partnerships, and research and development activities within the Pharmaceutical & Biotechnology Environmental Monitoring market on a global scale. Further, a detailed assessment of the pricing, marketing, and product development strategies adopted by leading market players is included in the Pharmaceutical & Biotechnology Environmental Monitoring market report.

Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Pharmaceutical & Biotechnology Environmental Monitoring market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pharmaceutical & Biotechnology Environmental Monitoring market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pharmaceutical & Biotechnology Environmental Monitoring market.The following players are covered in this report:Danaher CorporationThermo Fisher ScientificMerck KGaAEurofins SinensisLonzaBiomerieuxVAICosascoRMONIAmphenol Advanced SensorsVaisalaPharmaceutical & Biotechnology Environmental Monitoring Breakdown Data by TypeMonitoring EquipmentMediaSoftwareMicrobiology ServicesPharmaceutical & Biotechnology Environmental Monitoring Breakdown Data by ApplicationPharmaceutical IndustryBiotechnology IndustryAcademic & Research Institutes

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2641259&licType=S&source=atm

Read more from the original source:
COVID-19: Responding to the business impacts of Pharmaceutical & Biotechnology Environmental Monitoring Market Trends and Segments 2019-2027 ...

Read More...

Facilitating Research and Innovation: Establishment of 4 COVID-19 Bio Banks by the Department of Biotechnology – India Education Diary

May 31st, 2020 3:46 pm

New Delhi: For the mitigation of COVID-19 pandemic, R&D efforts are directed at the development of vaccines, diagnostics and therapeutics. The specimens collected from COVID-19 positive subjects can be a valuable resource for the R&D efforts. NITI Aayog has recently issued guidelines for sharing of bio specimens and data for research related to COVID-19. As per the directives of the Cabinet Secretary, the Indian Council of Medical Research (ICMR) has notified 16 bio-repositories for collecting, storing and maintaining clinical samples (oropharyngeal/ nasopharyngeal swabs, broncheoalveolar lavage, sputum, blood, urine and stool) of COVID-19 patients.

The enlistment of 16 Bio Repositories are as follows: ICMR 9, DBT 4 and CSIR 3. The four Bio Repositories under the purview of the Department of Biotechnology are, NCR-Biotech Science Cluster (i) THSTI, Faridabad Clinical samples (ii) RCB Faridabad Viral samples, Institute of Life Sciences, Bhubaneswar, InStem, Bangalore and ILBS, New Delhi .Oropharyngeal / nasopharyngeal swabs, bronchoalveolar lavage, sputum, blood, urine and stool of COVID19 patients will be collected and archived for future use to develop validated diagnostics, therapeutics, vaccines etc.

These designated facilities will develop uniform Standard Operating Procedures (SoPs) for sample collection, transportation, aliquoting, storage, and sharing. The role of bio-banks for COVID-19 samples would be development of a vaccine and treatments; guidance regarding handling, including nasopharyngeal swabs; and conditions under which the higher BSL-3 practices should be followed for example, when working with cultures of the coronavirus specimens. The Department of Biotechnology would be supporting these COVID-19 designated Bio-bank facilities through a well strategized future plan so that novel technological interventions can be developed in due course of time. These designated bio repositories will use the clinical samples for R&D purpose in their respective Institutes.

In addition, they are also authorized to share the samples with academia, industry and commercial entities involved in development of diagnostics, therapeutics, vaccines etc., after scrutinising the purpose of the request and ensuring benefit to the country. Sharing of Biospecimens both Clinical and Viral is going to be key for new technology and product development by our researchers, start-ups and industry, a critical step in our journey towards becoming an Atmanirbhar Bharat.

A Rapid Response Regulatory enabling mechanism facilitated by Department of Biotechnology for COVID 19

The Department of Biotechnology has taken several proactive measures to streamline the biosafety regulation and to facilitate researchers and industries which are undertaking research and development in Recombinant DNA Technology and Hazardous Microorganisms.

1. Operationalization of Indian Biosafety Knowledge Portal. The Indian Knowledge Biosafety Portal launched in May, 2019 was made fully operationalized and now the Department is receiving all new applications through online portal only. This has made the whole process transparent and time bound.

2. Notification of Revised Simplified Guidelines on Import, Export and Exchange of GE Organisms and Product Thereof for R&D Purpose: The Department issued the Revised Guidelines in January, 2020 in which Institutional Biosafety Committee have been delegated authority to take decisions on applications of import export and exchange of GE organisms and product thereof for R&D purpose for RG1 and RG2 items.

3. Facilitation of Research and Development on COVID-19: Considering the emerging situations of spread of Coronavirus and with the understanding on requirement of rapid research and development for COVI-19, the Department has proactively taken several steps to facilitate researchers and industries involved in research on COVID19. DBT has issued following guidelines, orders and checklist on COVID 19:

Rapid Response Regulatory Framework for COVID-19 to deal with application for development of vaccines, diagnostics, prophylactics and therapeutics has been notified on 20.03.2020DBT notified Interim Guidance Document on Laboratory Biosafety to Handle COVID-19 Specimens on 08.04.2020.IBSCs are allowed to conduct their meeting through video conferencing up to 30thJune, 2020.Rapid response regulatory framework for development of recombinant DNA COVID 19 vaccine was issued on 26.05.2020Scaling up of COVID testing centres (Hub and spoke model) inNationalresearch laboratories and Universities

To scale up testing and enhance the reach across the countryCity /Regional clusters have been established in a Hub and Spoke Model to scale-up testing of COVID-19 samples in government institutions across the country. Institutes and Laboratories which have the capacity and expertise for both sample collection, handling/processing (BSL-2 facility) and testing (RT-PCR) serve as the hubs and they involve a number of laboratories which have RT PCR machines and the requisite manpower as their extended Testing facilities.

The Hubs are Government laboratories approved by respective Ministries /Departments (DBT, DST, CSIR, DAE, DRDO, ICAR etc) as per ICMR guidelines. So far 19 City /Regional clusters have been established in Bangalore, Delhi/NCR, Hyderabad, Thiruvananthapuram, Chandigarh/Mohali, Bhubaneshwar, Nagpur, Pune, Mumbai, Lucknow, Chennai, Kolkata, North Eastern Region, Jammu & Kashmir, Ahmedabad, Madhya Pradesh, Rajasthan, Banaras, Palampur and Delhi city.

About 100 institutions have been involved and over 1,60,000 samples tested. Seven DBT Autonomous institutes have been approved as hubs by ICMR and they are performing testing for diagnosis of COVID-19 (RGCB, THSTI, ILS, inStem, NCCS, CDFD, NIBMG).

They are also functioning as hubs in the respective Cities/Regions and coordinating the efforts with a number of other premier Central and State Government institutions. In addition, they are working closely with the respective State Governments in obtaining samples for testing and are reporting every day to ICMR on their testing results. Collectively in about 4 weeks, these clusters have done nearly 1,70,000 tests. These clusters will now be scaled to nearly 50 in next 4 weeks and reach remote corners of the country.

Visit link:
Facilitating Research and Innovation: Establishment of 4 COVID-19 Bio Banks by the Department of Biotechnology - India Education Diary

Read More...

Regenerative Therapies: Helping Horses Self-Heal The Horse – TheHorse.com

May 31st, 2020 3:45 pm

The art (and existing science) of regenerative medicine in equine practice, and whats to come

Regenerative therapy is an umbrellaterm encompassing any method that encourages the body to self- heal. Because it is drawing onits own properties, healing tissue more closely resembles native tissue than weak, disorganized scar tissue typically seen post-injury.

The goal is to allow restoration of normal function and structure of the injured tissue to allow horses to perform at their previous level, whatever that might be, with a reduced risk of reinjury, says Kyla Ortved, DVM, PhD, Dipl. ACVS, ACVSMR, assistant professor of large animal surgery at the University of Pennsylvanias New Bolton Center, in Kennett Square.

She says the three main components of regenerative medicine that help tissues self-heal include:

A specific therapy may incorporate some or all three of these components, says Ortved.

Due to the regenerative therapy industrys popularity and continued growth, many articles weve published review recent laboratory studies about stem cell production and data on efficacy andsafety (you can find them at TheHorse.com/topics/regenerative-medicine). Here, well review the basics of three regenerative modalities commonly used in equine medicine and when veterinarians and horse owners might consider each.

With this approach the practitioner collects blood from a horse and processes it using a commercial system that concentrates the platelets. When he or she injects that concentrated platelet product back into the horse, granules within the platelets release an array of growth factors that aim to facilitate and modulate the healing process. Specifically, granule-derived growth factors encourage target tissue cells at the injury site to migrate and proliferate, improve extracellular matrix synthesis, and stimulate blood vessel development.

Recently, leukocyte-reduced PRP hasbecome many equine veterinarians PRP product of choice. These preparations contain fewer white blood cells (leukocytes) and, reportedly, inflammatory mediators than normal PRP products do. These mediators break tissues down, effectively counteracting the anabolic (tissue-building) effects of the platelets and their granules.

Veterinarians can easily prepare ACS by collecting a blood sample from the patient, then incubating it with special commercially available glass beads to stimulate interleukin-1 receptor antago- nist protein (IRAP) production. Theythen inject the resultant IRAP-rich serumsample back into the patient at the target location or injury site. This protein blocks the action of interleukin-1, a powerful and damaging pro-inflammatory mediator. Additionally, glass bead incubation stimulates the production of anti-inflammatory mediators and growth factors similar to those found in PRP.

Ortved says its important to remember that all biologics, including PRP and IRAP, contain various concentrations of growth factors and bioactive protein.

Remember, they are made from your horses blood and, therefore, containall of the components in blood, just in varying concentrations, she says.

Regenerative therapies that contain highconcentrations of IRAP include IRAP II, autologous protein solution (APS), and bone marrow aspirate concentrate (BMAC).

In certain tissues, such as adipose (fat) and bone marrow, we can find specific cells that have the ability to self-renew and grow more than 200 types of body cells. Veterinarians can isolate these cells, called stem cells or progenitor cells, and either:

Perhaps more important than theirability to differentiate into other celltypes, stem cells have powerful anti-inflammatoryproperties and play acentral role in coordinating healing in alltypes of tissues through cell-to-cell signaling,Ortved says.

Which of these three modality typeswill provide the most benefit to yourhorse depends on a variety of factors thatyou and your veterinarian will consider.

Follow this link:
Regenerative Therapies: Helping Horses Self-Heal The Horse - TheHorse.com

Read More...

AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A -…

May 31st, 2020 3:45 pm

Sernova to utilize AgeXs UniverCyteTM gene technology to generate transplantable, universal immune-protected therapeutic cells for Sernovas Cell PouchTM Platform

ALAMEDA, Calif. & LONDON, Ontario--(BUSINESS WIRE)--AgeX Therapeutics, Inc.(AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today a research collaboration where Sernova will utilize AgeXs UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for use in combination with Sernovas Cell PouchTM for the treatment of type I diabetes and hemophilia A. The goal is to eliminate the need for immunosuppressive medications following Cell Pouch cell transplantation.

The research collaboration will evaluate whether Sernovas pluripotent stem cell-derived pancreatic islet beta cells engineered with AgeXs UniverCyte technology can evade human immune detection. The complementary combination of technologies could enable the transplantation of therapeutic cells in patients with type I diabetes in an off-the-shelf manner using Sernovas Cell Pouch, without human leukocyte antigen (HLA) tissue matching or concurrent administration of immunosuppressive medications. With a similar intent, pluripotent stem cell-derived or adult donor-derived human Factor VIII-releasing cells modified with AgeXs UniverCyte will be evaluated in Sernovas hemophilia A program.

Under the terms of the agreement, Sernova has been granted a time-limited, non-exclusive research license by AgeX. A commercial license for Sernova to utilize UniverCyte to engineer cellular products for therapeutic and commercial purposes may be negotiated between the companies pending successful study outcomes.

The UniverCyte technology aims to mask therapeutic cells derived from pluripotent stem cells or adult donors from human immune detection to allow for off-the-shelf cellular products without the need for immunosuppressant medications which may have potent side effects, or HLA-matching between donor and patient. UniverCyte uses a novel, modified form of HLA-G, a potent immunomodulatory molecule, which in nature protects an unborn child from their mothers immune system. In almost all human cells, native HLA-G expression is silenced after birth. AgeXs modified HLA-G shows evidence of being resistant to this silencing, thereby potentially allowing for long-term, stable and high expression of the immunomodulatory effect.

Sernova plans to utilize the universal therapeutic cells generated through this research collaboration with its Cell Pouch System, a proprietary, scalable, implantable macro-encapsulation device, which, upon implantation, incorporates with tissue and forms highly vascularized chambers. These chambers become a natural environment in the body to house and favor long-term survival and function of therapeutic cells. The Cell Pouch System has shown initial safety and efficacy indicators in an ongoing Phase I/II clinical study at the University of Chicago and in a preclinical model of hemophilia A when assessed with human cells corrected to produce Factor VIII.

We are thrilled with our collaboration with Sernova, which is at the forefront of cellular therapies for diabetes and hemophilia and is already in the clinic for the former. The combination of AgeXs UniverCyte to cloak cells from a patients immune system and Sernovas Cell Pouch technologies to permit cells to function long-term upon transplantation would be a landmark for regenerative medicine. This deal marks another important step in AgeXs collaboration and licensing strategy to work with the very best people, companies and institutions in the world of regenerative medicine, said Dr. Nafees Malik, Chief Operating Officer of AgeX.

We look forward to working with AgeX and its outstanding team as we continue to identify and evaluate technologies complementary to Sernovas therapeutic platform and expand our immune protection offerings. AgeXs UniverCyte technology is a significant advancement in the field of cell therapy and a perfect fit with Sernovas Cell Pouch technologies and therapeutic pipeline with its potential benefit over current immunosuppressive strategies for regenerative medicine therapeutics, said Dr. Philip Toleikis, President and CEO of Sernova Corp.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About Sernova Corp.

Sernova Corp is developing regenerative medicine therapeutic technologies using the Cell Pouch System, a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit http://www.sernova.com.

Forward-Looking Statements for AgeX

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, there can be no assurance that Sernovas planned use of AgeXs UniverCyteTM gene technology will successfully generate immune-protected universal therapeutic cells for use in combination with Sernovas Cell PouchTM for the treatment of type I diabetes and hemophilia A or any other disease, and there can be no assurance that AgeX and Sernova will enter into a commercial license for the use of UniverCyteTM in a therapeutic or other product. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Forward-Looking Statements for Sernova

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words expects, plans, anticipates, believes, intends, estimates, projects, potential and similar expressions, or that events or conditions will, would, may, could or should occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements including those related to the potential of Univercyte combined with Sernovas technologies are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernovas management on the date such statements were made, which include our beliefs about the effect on company operations of the COVID-19 virus and conduct and outcome of discussions, clinical programs, and our clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200529005130/en/

Visit link:
AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A -...

Read More...

Rheumatoid Arthritis | Early Signs, Causes and Treatment – DrugWatch.com

May 31st, 2020 2:44 am

About 1.5 million Americans have RA, according to the Arthritis Foundation. Arthritis most commonly affects older people, but RA can start at any age. It affects both women and men, but its three times more likely to develop in women.

Unlike the most common type of arthritis, osteoarthritis, RA symptoms include fatigue, fever and a loss of appetite in addition to painful, stiff joints. If people experience pain in a joint on one side of the body, it is likely to also affect the same joint on the other side of the body.

There is no cure for RA, and its a progressive disease meaning it gets worse over time. Severe forms of the disease can be disabling and disfigure joints. People cannot die from rheumatoid arthritis, but it can cause complications that may be life-threatening.

Treatments can help people with the disease lead productive lives, and early diagnosis helps control joint damage before it becomes severe.

Expand

Typically, the first sign of rheumatoid arthritis is stiffness, followed by pain and tenderness in the joints. These symptoms can worsen slowly over weeks or months. Most often, symptoms start in smaller joints such as fingers and toes, and then move to other joints.

The number of joints affected varies, but RA most often attacks five or more joints. It may start as swelling that comes and goes, lasting for a few days or weeks at a time, but it gradually gets worse.

Symptoms may also worsen and occur in intense attacks called flares when triggered by stress, suddenly stopping medications or too much activity, according to National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Common RA symptoms include:

Because RA is an autoimmune disease, it can affect the entire body and attack the eyes, heart, glands, nails and nerves.

Expand

RA is caused when the immune system attacks healthy joint tissues. Researchers dont know what causes the immune system to attack the synovium, the lining of the joints. But this process causes inflammation that can destroy bone and cartilage, stretching and weakening tendons and ligaments.

This leads to pain and loss of joint shape and alignment.

While researchers dont know the exact cause, several risk factors can make someone more likely to get RA. Women are more likely to get RA, but according to the Centers for Disease Control and Prevention, women who breastfed their infants have a decreased risk.

Factors that increase risk include:

AgeWhile RA can affect people of all ages, the risk of developing it increases with age, especially for adults in their 60s.

Female SexWomen are 2-3 times more likely to have RA than men.

SmokingPeople who smoke are more likely to develop RA, and smoking makes symptoms worse. Children exposed to secondhand smoke have double the risk of developing RA.

Live BirthThe risk of RA may be greater in women who have never given birth.

Environmental exposuresExposure to toxic substances such as chemicals, asbestos or silica may increase the risk of developing rheumatoid arthritis.

ObesityBeing overweight increases the risk of RA, especially in women 55 or younger.

Research suggests that people born with specific genes called HLA (human leukocyte antigen) class II genotypes are more likely to develop RA. These genes can also make symptoms worse. In people who are obese or who smoke, the risk is highest.

People with relatives who have RA are also at increased risk of developing the disease.

People with rheumatoid arthritis are at risk of developing other health problems. In addition to physical issues, people with RA can also have difficulty keeping or finding employment because of physical limitations such as pain and fatigue.

People with RA have an increased risk of other health problems, such as:

There are three main types of RA. While symptom severity in each type may be different, the treatments are the same.

About 80 percent of people with RA have this type of disease, according to the Illinois Bone & Joint Institute. This means blood tests showed a protein called rheumatoid factor (RF) and antibodies called anti-citrullinated protein antibodies (ACPAs). This type of RA can have more severe symptoms than seronegative RA.

People with this type of RA dont test positive for antibodies or proteins, but they still have RA symptoms. They are also less likely to have complications such as lung issues, heart problems and inflamed blood vessels.

Juvenile idiopathic arthritis affects children ages 17 years old and younger and may sometimes be called juvenile rheumatoid arthritis. It has many of the same symptoms as adult RA but can also cause difficulty gaining weight and growing. Unlike adult RA which is a lifelong condition, children can outgrow JIA.

Doctors that specialize in diagnosing RA and other types of arthritis are called rheumatologists. If your primary care provider suspects you might have RA or another type of arthritis, he or she may refer you to a rheumatologist for testing.

A rheumatologist will diagnose RA based on several tests. These include blood tests, imaging tests such as X-rays and MRIs and a physical examination.

Blood tests search for a protein called rheumatoid factor (RF) and antibodies called anticitrullinated protein antibodies (anti-CCP). Other tests such as the erythrocyte sedimentation rate (ESR) test and C-reactive protein test can find high levels of inflammation present in people with RA.

These tests also help doctors distinguish RA from other types of arthritis such as gout, osteoarthritis, lupus and psoriatic arthritis.

RA has four stages that progress in severity. The stage of disease can influence treatment.

Stage 1Early stage RA with some swelling and stiffness in joints.

Stage 2Moderate stage RA with cartilage damage. Difficulty moving joints occurs more often.

Stage 3Severe disease that destroys bone and cartilage. Increased pain, swelling, decrease in mobility and loss of muscle strength. Joints may begin to deform.

Stage 4End stage RA where joints stop functioning. Symptoms include severe pain, swelling, stiffness and loss of mobility.

People with RA and OA have pain in the joints and difficulty moving around, but there are a few differences in severity of symptoms and how they manifest.

Characteristics of RA and OA

Treatment options for RA include medication, occupational therapy and surgery. In addition, lifestyle changes and assistive devices are things people with RA can do to manage symptoms at home.

Doctors will prescribe treatments depending on the stage of disease, severity of symptoms and degree of inflammation.

Several types of medications treat RA, and a doctor considers how long a patient has had the disease and the severity of symptoms when choosing a medication. Sometimes, people may have more than one prescription.

Over-the-counter NSAIDs such as ibuprofen (Advil, Motrin IB) and naproxen sodium (Aleve) can relieve pain and inflammation. Stronger NSAIDs are available by prescription.

These medications, such as prednisone, reduce pain and inflammation. They can also slow joint damage. These medications are usually prescribed for acute symptoms and patients gradually stop them.

DMARDs can slow the progression of RA and save tissues and joints from permanent damage. Common DMARDs include methotrexate and hydroxychloroquine, also known as Plaquenil.

These drugs, also known as biologic response modifiers, are a newer class of DMARD. They target parts of the immune system to control joint and tissue damage. Drugs in this class include Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Actemra (tocilizumab) and Xeljanz (tofacitinib).

Occupational therapists can help people with RA learn to better manage their symptoms. Patients can learn how to do daily chores with less pain, how to protect their joints and how to use assistive devices to make daily tasks easier. Evidence from studies shows that occupational therapy helps people with RA do daily chores without pain and better protect their joints, according to a Cochrane review.

In cases of severe RA disease, surgery may be able to help regain some mobility and decrease pain.

In arthroplasty, the affected joint is replaced or reconstructed. This surgery can restore joint function, fix a deformity, relieve pain and stiffness, and improve mobility.

In this procedure, surgeons remove damaged or inflamed tissue without replacing or reconstructing a joint. It can restore joint function and relieve pain.

This type of surgery is also called nerve decompression surgery. It helps relieve pain caused by impinged nerves. This restores strength to the affected joints affected by RA, including elbows, feet, toes and wrists.

A synovectomy is surgery to remove the diseased synovial lining in a joint. It reduces swelling, alleviates pain, and can help prevent or slow down damage to the joint.

Hand and wrist surgery can repair damaged tendons and ligaments in the hands. It helps restore movement to the joints in the hands, wrists and fingers.

In addition to medication and surgery, patients may want to ask their doctor about simple therapies they can do at home, such as exercise and diet.

Low impact exercises can strengthen muscles and improve flexibility. These include walking, water aerobics, swimming and yoga.

According to a 2012 review published in Open Access Journal of Sports Medicine by Shirley Telles and Nilkamal Singh, yoga has shown some promise in reducing pain, improving function and providing mental health benefits.

A small 2019 study by researcher Surabhi Gautam and colleagues published in Restorative Neurology and Neuroscience found that yoga eased physical symptoms and improved mental health.

Evidence suggests that eating a healthy diet with anti-inflammatory foods can ease RA symptoms. There isnt a specific regimen to follow, but a 2018 review recommended the Mediterranean diet and fish oil for people with RA, Today reported.

In general, keeping a healthy weight and getting the proper nutrition helps manage inflammation that can worsen RA.

Foods that may manage RA symptoms include:

People with RA often suffer from fatigue and pain that can get worse during flare-ups. Make sure to get plenty of rest.

Heating pads or warm showers and cold packs can help ease inflammation, pain and stiffness.

Assistive devices such as canes, splints and braces can ease strain on joints and keep them in proper alignment. Household aids such as handrails or grab bars can help people stay safe and prevent injury.

Occupational therapists can help people learn how to use assistive devices.

RA symptoms can affect all aspects of a persons life, including work, social and leisure activities. The CDC has recommendations for improving quality of life for people with RA.

Aim to stay active for 30 minutes a day, five days a week. These 30-minute sessions can be done all at once or broken up into 10-minute sessions throughout the day.

Walking, swimming, yoga or bicycling can be effective exercises to improve cardiovascular health, flexibility and muscle strength in people with RA. Always check with your doctor before starting an exercise routine.

If exercising alone seems daunting, join a group fitness class or activity session at a local community center or other facility. These classes can teach people how to exercise effectively and safely. Plus, meeting with others can help improve mood.

Physical therapists may also be able to teach a person with RA how to properly exercise to help reduce pain and increase mobility.

People with RA who take a self-management class can learn more about arthritis, learn tips for living with the disease and learn how to control symptoms. Examples of CDC-recommended programs include Arthritis Self-Management Program (ASMP) and Chronic Disease Self-Management Program (CDSMP).

Learn more about CDC-recognized programs proven to teach people with RA and arthritis how to manage their conditions.

Smoking increases the severity of RA symptoms and can cause other medical problems. Ask your doctor for help in quitting or visit the CDCs How to Quit Smoking page.

Read the rest here:
Rheumatoid Arthritis | Early Signs, Causes and Treatment - DrugWatch.com

Read More...

20 Best Foods to Ease Arthritis Pain and Reduce Inflammation – Parade

May 31st, 2020 2:44 am

It has been estimated that over 50,000 Americans are diagnosed with some form of arthritis every year. Arthritis comes with pain that may vary in frequency but commonly goes unresolved for years or even a lifetime. Treatment for chronic pain, such as arthritis, begins with addressing overall healthincluding sleep, diet and mood. While just one component of treatment, eating the best foods for arthritis can play a role in easing pain and preventing some conditions often related to the presence of arthritis.

Related:How to Keep Your Joints Healthy

After an arthritis diagnosis, taking a look at what you eat is a common starting point. There are two main benefits to improved nutrition: easing pain by adding foods that relieve arthritis and removing foods that make arthritis worse and reaching a healthy body mass index (BMI).It is important to note that an arthritis-friendly diet shouldnt replace medications, other therapies or recommendations from your rheumatologist.

The medicines that you take [for arthritis] work better in a normal BMI; studies have shown when you are at a higher BMI, the medicines dont work as well, explains M. Elaine Husni MD, MPH, vice chair of the Department of Immunologic and Rheumatic Disease and director of the Arthritis Center at Cleveland Clinic. In that case, diet becomes important not only for nutritional value but also for your treatment outcome. You will reduce a lot of comorbidities or complications of the disease.

Even someone who had the cleanest diet before an arthritis diagnosis may find adding certain foods can help alleviate pain and symptoms. Marcy OKoon, senior director of consumer health at the Arthritis Foundation, explains that while food cannot cause or cure arthritis, it can hurt or help it.

Overcoming Family History Just because your parent has arthritis doesnt mean you will. You may be more prone to arthritis, but researchers are still studying the role of genetics as a determining factor.

Osteoarthritis is the most common form of arthritis, affecting the joints as the cartilage wears down between the bones. In this case, the CDC notes that obesity can put extra pressure on joints, increasing swelling that already is a common cause of osteoarthritis.

As with all types of arthritis, doctors stress eating a healthy diet with as little processed food as possible. What we generally recommend in any case is to have a nutrient dense diet, Dr. Husni says. That means everything you put in your body we want to make sure is healthy and packed full of nutrients; we dont really want you filling with empty calories.

The best foods for easing arthritis symptoms are actually foods that are good for everyone; however, from an arthritis standpoint, OKoon recommends learning which foods are pro-inflammatory and which are anti-inflammatoryand steering away from foods that make arthritis worse. For example, processed salty and crunchy snacksparticularly those containing glutenare going to increase inflammation. Nutrient-dense foods such as blueberries contain antioxidants that lessen inflammationand can help reduce the swelling that all types of arthritis cause.

When looking for a specific type of diet, the Mediterranean diet is often cited as a great starting point because it focuses on plant-based, minimally processed foods. Eating more whole foods can also help with weight management, which is often a focus of arthritis treatment that helps medications work better.

Related:What Does Arthritis Feel Like?

Rheumatoid arthritis (RA) is an autoimmune form of arthritis thataffects over a million Americans. It triggers inflammatory chemicals that attack and damage the bodys own joints and tissues, rather than a viral or bacterial invader, OKoon says.

Obesity is actually a risk factor for RA, but there are other health issues that can be attributed to the disease. For example, those with RA have a higher risk of developing heart disease and diabetes, so nutrition in this case would be a vital part of managing life with arthritis.

Just as with osteoarthritis, you should be eating foods that are nutrient rich and reducing processed foods in your diet. Dr. Husni stresses the importance of getting nutrients from your food versus supplements; taking a turmeric pill to get more omega-3 fatty acids isnt the same as eating a piece of fresh salmon. Getting your nutrients in their most natural form is always best. That means changing how you eat fruits and vegetableslike consuming them raw vs. cookedcan help your body get more nutrients.

Related: Rheumatoid Arthritis and Diet

Psoriatic arthritis (PsA) is an inflammatory disease that attacks where tendons and ligaments connect to the bone,causing inflammation in the joints. For the same reasons, eating a healthful dietwhich is also low calorie if weight loss is neededis a smart part of an overall management plan, OKoon adds.

Just as with RA there is a risk of heart disease with PsA, however, the risk nearly doubles if you have a PsA diagnosis. Again, this is why people with PsA should follow the same guidelines for other types of arthritis. In this case, eating foods that are heart healthysuch as berries, nuts and leafy, green vegetablesshould be a focus.

Related:Know the 5 Types of Psoriatic Arthritis

Make sure you actually like whatever healthy foods you choose so your changes can be long-term and sustainable. Additionally, recognizing that other lifestyle factors go hand-in-hand with a healthy diet is important; what you eat is just a piece of the larger puzzle.

If you are on the best diet but smoke a pack of cigarettes per day, your diet wont matter, notes Husni. Stress, sleep, etc. is all intertwined; you have to be mindful of the other lifestyle factors that go along with having a good diet.

If your doctor has spoken to you about ways to ease arthritis pain with some dietary changes, here are some of the best foods to add into your meals that can help keep inflammation down, manage weight and provide you with essential vitamins and minerals for a strong body (and bones).

Celebrity interviews, recipes and health tips delivered to yourinbox.

5 Foods That Lower Inflammation:

5 Foods High in Omega-3 Fatty Acids:

5 Nutrient-Dense Fruits and Vegetables:

5 Staples of the Mediterranean Diet:

Next,What Is Restorative Yoga and How Will It Help You

More here:
20 Best Foods to Ease Arthritis Pain and Reduce Inflammation - Parade

Read More...

Study Demonstrates Link Between Rheumatoid Arthritis and Insulin Resistance – Rheumatology Network

May 31st, 2020 2:44 am

Rheumatoid arthritis and diabetes may be closely related, according to researchers writing in the June issue of Arthritis and Rheumatology.

Led by Ronan H. Mullan, MBCHB, Ph.D., of Trinity Centre for Health Science, Ireland, researchers conducted a study of 92 rheumatoid arthritis and osteoarthritis patients finding that insulin resistance was independently associated with a high body mass index (61 patients) and swollen joint count in 28 joints (61 patients).

Both type 2 diabetes mellitus and chronic inflammatory diseases, including rheumatoid arthritis, are characterized by increased insulin resistance, a phenomenon that is thought to be a contributor to adverse cardiovascular outcomes in rheumatoid arthritis through nontraditional mechanisms, the authors wrote.

The findings are based on an assessment of disease activity in rheumatoid arthritis patients. They were assessed for cardiovascular risk factors, including insulin resistance and body mass index.

The study included 92 patients of which 66% were female and 72% were positive for rheumatoid factor. At baseline, the mean values for swollen joint count in 28 joints (SJC28), tender joint count in 28 joints (TJC28), and Disease Activity Score in 28 joints (DAS28) were 3.7 4.4, 3.6 5.2, and 3.5 1.5, respectively. The mean BMI was 28 7 kg/m with 70% of patients having a BMI higher than >25 kg/m. Insulin resistence was present in 26% of patients and 5% of patients had diabetes. They patients were being treated with DMARDs (80%), biologics (29%), and steroids (19%).

The patients, including a second group with osteoarthritis, underwent synovial tissue testing for glucose transporter 1 (GLUT 1) and GLUT4 activity. GLUT-1 expression was greater in the synovium of rheumatoid arthritis (RA) patients (n = 26) as compared to patients with osteoarthritis (n = 16). RA patients showed increased expression in the lining, sublining, and vascular regions. But, decreased GLUT4 expression was found in the RA lining layer in 21 patients as compared to only eight osteoarthritis patients.

When GLUT-1 protein expression decreased, pAMPK protein expression in synovial fluid increased in in four patients who were treated with metformin, which increased glycolytic activity and decreased oxidative phosphorylation in rheumatoid arthritis synovial fibroblasts in seven patients. RA patients who were taking metformin or aminoimidazole carboxamide ribonucleotide, demonstrated a reduced spontaneous production of interleukin6 (IL 6), IL 8, and monocyte chemotactic protein 1 in synovial explants and fibroblasts.

The results of the present study highlight a relationship between insulin resistance and disease activity in rheumatoid arthritis. Furthermore, we demonstrated downregulation of inflammatory responses in ex vivo rheumatoid arthritis synovial explant cultures and rheumatoid arthritis synovial fibroblasts cell cultures by metformin, as well as evidence to suggest that alteration in glucose pathways may ameliorate disease activity in rheumatoid arthritis, they wrote.

REFERNCE:Lorna Gallagher Sian Cregan Monika Biniecka Clare Cunningham Douglas J. Veale David J. Kane Ursula Fearon Ronan H. Mullan. "InsulinResistant Pathways Are Associated With Disease Activity in Rheumatoid Arthritis and Are Subject to Disease Modification Through Metabolic Reprogramming: A Potential Novel Therapeutic Approach," Arthritis and Rheumatology. Frst published:16 December 2019 https://doi.org/10.1002/art.41190

Read more:
Study Demonstrates Link Between Rheumatoid Arthritis and Insulin Resistance - Rheumatology Network

Read More...

Rheumatology Drugs Explored for COVID-19 in the Spotlight – Medscape

May 31st, 2020 2:44 am

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

First results from a database of adults and children with rheumatic and musculoskeletal diseases who have contracted COVID-19 will be unveiled at the upcoming virtual European League Against Rheumatism (EULAR) 2020 Congress.

Loreto Carmona

The database, which is updated weekly, will enable clinicians to compare treatment and disease outcomes in patients and to analyze predictive factors for poor prognoses, said Loreto Carmona, MD, PhD, from the Musculoskeletal Health Institute in Madrid, who is chair of the EULAR abstract selection committee.

As of May26, a total of 985 patients from 28 participating countries had been entered in the EULAR COVID-19 database, which was launched as part of the Global Rheumatology Alliance. Patient data are categorized by factors such as top rheumatology diagnosis, comorbidities, top-five COVID-19 symptoms, and disease-modifying anti-rheumatic drug (DMARD) therapy at time of virus infection. Anonymized data will be shared with an international register based in the United States.

In addition to the "many questions" about which immunomodulatory drugs can make patients with rheumatic and musculoskeletal diseases more vulnerable to the virus, rheumatologists and patients also want to know if any standard therapies can prevent the cytokine storms that are a severe complication of the disease, Carmona explained.

"There are also questions about whether some of our treatments are actually masking the disease, or if we might have complications or different safety events because of that," she told Medscape Medical News.

"This crisis is going scarily fast," Carmona pointed out. "Some of the answers are not really complete and we are still waiting for some good clinical trials, but we suspect that some of the DMARD medications are actually playing a good part in this disease."

"There are real implications for our patients," said John Isaacs, MBBS, PhD, from Newcastle University in Newcastle Upon Tyne, United Kingdom, who is chair of the EULAR scientific program committee. "We can't make assumptions we have to do trials but the answers to these questions will determine the lifestyles of our patients and the decisions they make."

John Isaacs

"COVID-19 is a very interesting situation for all sorts of reasons, and not least because a lot of the drugs we use in rheumatology are being investigated as potential treatments for severe COVID," he told Medscape Medical News.

"That means our community has had quite a lot of input into COVID, and patients want to know if they are at risk for it or, conversely, if they may be safeguarded because of some treatment they're receiving," he said.

The many sessions scheduled for the original meeting remain dedicated to research on treatment options for rheumatoid arthritis, lupus, scleroderma, and other rheumatic and musculoskeletal diseases, but much of the focus has naturally shifted to COVID-19, the organizers said.

As it has in typical years, the meeting will be dominated by research on rheumatoid arthritis, especially into potential new targets. Several noteworthy abstracts will home in on thrombosis risk related to inflammatory arthritis treatments, Isaacs reported.

Another abstract will focus on opioid analgesic consumption in patients also taking TNF inhibitors. This will be interesting because "I know there's some concern about the amount of opioid use in people with arthritis right now," he added.

European League Against Rheumatism (EULAR) 2020 Congress.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more:
Rheumatology Drugs Explored for COVID-19 in the Spotlight - Medscape

Read More...

Page 521«..1020..520521522523..530540..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick